Skip to main content
. 2019 Mar 20;8(1):30. doi: 10.3390/antibiotics8010030

Table 3.

Summary of trials for the use of ceftaroline in adult patients with MRSA infection. (ABSSSI = Acute bacterial skin and skin structure infection; CABP = community-acquired bacterial pneumonia; SAB = Staphylococcus aureus bacteremia).

Criteria Ho et al. [20] Casapao et al. [21] Vazquez et al. [22] Lin et al. [23] Polenakovitch et al. [24] Sakoulas et al. [25] Santos et al. [26]
Total number of patients who received ceftaroline, n 6 630 48 (27 with ABSSSI and 21 with CABP) 10 31 26 647
Patients with MRSA, n (%) 6 (100%) 241 (38%) 16 (59%) with ABSSSI and 16 (76%) with CABP 10 (100%) 31 (100%) 20 (76%) 191 (29%)
Patients who received antibiotics prior to ceftaroline 6 422 14 with ABSSSI and 13 with SAB 10 31 26 515
Duration of treatment with ceftaroline, median (range) Varies per case 6 days 5.8 days for ABSSSI and 7 days for CABP Varies per case 5 days 16 days 6 days
Number of patients that were treated with ceftaroline as monotherapy 6 447 22 in ABSSSI and 10 in CABP - - none 114
Clinical success of MRSA patients, n (%) 5 (83%) 426/484 (88%) 8/16 (50%) with ABSSSI
And 10/16 (63%) with CABP
6 (60%) 23 (74%) 23 (88%) 144/178 (81%)
Safety outcome GI bleeding and death reported in one patient 8% hospital mortality
0.9% diarrhea
0.6% vomiting
1.1% renal failure
- Rash, eosinophilia, pruritis and clostridium difficile infection Eosinophilic pneumonia, rash and diarrhea - -